Previous 10 | Next 10 |
2023-08-02 06:04:22 ET Ares Commercial Real Estate press release ( ACRE ): Q2 GAAP EPS of $0.04. Revenue of $24.99M (-0.6% Y/Y). For further details see: Ares Commercial Real Estate GAAP EPS of $0.04, revenue of $24.99M
2023-06-26 12:39:40 ET Pharmaceutical company Acer Therapeutics ( NASDAQ: ACER ) said on Monday that CEO and Founder Christopher Schelling has infused $1M into the company in exchange for a promissory note. The company has issued a $1M unsecured, subordinated promissory n...
Promissory note extends cash runway into early Q3 2023 OLPRUVA™ expected to be available by prescription in the U.S. beginning July 5 th NEWTON, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company...
NEWTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial...
Availability: OLPRUVA™ drug in channel now anticipated in mid-June 2023 Awareness: 70% of metabolic treatment providers surveyed by Acer at SIMD Annual Meeting indicated an interest in treating at least one of their patients with OLPRUVA™ in 2023 Reimbursement: Ace...
2023-03-27 17:02:39 ET Acer Therapeutics press release ( NASDAQ: ACER ): Q4 GAAP EPS of -$0.54 misses by $0.17 . Ended Q4 2022 with $2.3 million in cash and cash equivalents. Acer believes its cash and cash equivalents available at December 31, 2022, together with the ...
NEWTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financi...
NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today...
2023-03-22 08:12:30 ET Acer Therapeutics ( NASDAQ: ACER ) shares dropped 7% premarket on Wednesday after the pharmaceutical company announced a $2.675M securities offering priced at-the-market under Nasdaq rules. The offering comprises 2,920,306 shares of the company...
NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023